Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) CFO Sells 5,886 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) CFO Adam Laponis sold 5,886 shares of the business's stock in a transaction on Friday, January 10th. The shares were sold at an average price of $43.26, for a total transaction of $254,628.36. Following the transaction, the chief financial officer now owns 110,096 shares of the company's stock, valued at $4,762,752.96. This trade represents a 5.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Adam Laponis also recently made the following trade(s):

• On Wednesday, November 6th, Adam Laponis sold 4,160 shares of Twist Bioscience stock. The stock was sold at an average price of $44.60, for a total transaction of $185,536.00.

Twist Bioscience Trading Down 1.9 %

Shares of TWST traded down $0.83 during trading hours on Tuesday, reaching $42.75. 916,120 shares of the company traded hands, compared to its average volume of 688,190. The firm has a market cap of $2.54 billion, a price-to-earnings ratio of -11.88 and a beta of 1.85. The stock's fifty day moving average price is $46.43 and its 200 day moving average price is $46.38. Twist Bioscience Co. has a 12-month low of $27.41 and a 12-month high of $60.90.

Hedge Funds Weigh In On Twist Bioscience

A number of hedge funds and other institutional investors have recently modified their holdings of TWST. Principal Financial Group Inc. boosted its holdings in shares of Twist Bioscience by 67.5% in the 3rd quarter. Principal Financial Group Inc. now owns 205,864 shares of the company's stock valued at $9,301,000 after buying an additional 82,953 shares in the last quarter. Oddo BHF Asset Management Sas acquired a new position in shares of Twist Bioscience during the third quarter worth $3,302,000. Beaird Harris Wealth Management LLC purchased a new position in Twist Bioscience during the 3rd quarter worth $95,000. Franklin Resources Inc. increased its position in Twist Bioscience by 3.4% during the 3rd quarter. Franklin Resources Inc. now owns 252,064 shares of the company's stock valued at $11,756,000 after buying an additional 8,308 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB purchased a new stake in Twist Bioscience in the third quarter valued at about $34,000.

Wall Street Analysts Forecast Growth

TWST has been the subject of a number of recent research reports. Robert W. Baird boosted their price objective on shares of Twist Bioscience from $46.00 to $48.00 and gave the stock an "outperform" rating in a report on Tuesday, November 19th. TD Cowen restated a "buy" rating and issued a $58.00 price objective on shares of Twist Bioscience in a report on Tuesday, November 26th. Leerink Partners increased their price objective on Twist Bioscience from $45.00 to $48.00 and gave the stock a "market perform" rating in a report on Thursday, October 17th. Evercore ISI boosted their target price on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an "outperform" rating in a report on Tuesday, October 1st. Finally, Wolfe Research began coverage on shares of Twist Bioscience in a research note on Friday, December 13th. They issued an "outperform" rating and a $60.00 price target for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $51.90.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.